Rapporto sull’analisi delle dimensioni del mercato e dell’analisi delle quote del trattamento della sindrome dell’intestino irritabile | Previsioni 2031

  • Report Code : TIPRE00006814
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 180
Buy Now

Il mercato del trattamento della sindrome dell'intestino irritabile (IBS) è stato valutato a 2.153,89 milioni di dollari nel 2020 e si prevede che raggiungerà 4.600,30 milioni di dollari entro il 2028; si prevede che crescerà a un CAGR del 10,1% dal 2021 al 2028.

I fattori principali come la crescente prevalenza delle malattie della sindrome dell'intestino irritabile e l'aumento della ricerca e della ricerca. le attività di sviluppo guidano la crescita del mercato. Tuttavia, la disponibilità limitata di prodotti e l’inefficienza del trattamento frenano la crescita del mercato. L'IBS è una condizione cronica comune che colpisce l'organo addominale, l'intestino crasso. È noto anche come colon spastico, colite mucosa, colon irritabile e colite spastica. La condizione è molto diversa dalla malattia infiammatoria intestinale. Mostra sintomi come crampi, dolore addominale, gonfiore, gas e diarrea o stitichezza, o entrambi allo stesso tempo. Se i sintomi sono lievi, possono essere gestiti modificando lo stress, lo stile di vita e la dieta. D’altro canto, i sintomi gravi vengono trattati con farmaci e consulenza.

Nell'APAC sono state implementate molte misure per contenere la diffusione del nuovo coronavirus che causa il COVID-19. Le misure hanno interrotto le operazioni di molte aziende in vari settori, compreso quello sanitario. La quarantena del personale, i fallimenti della catena di approvvigionamento e la riduzione della domanda hanno generato gravi complicazioni per le aziende. Inoltre, si è registrato un calo significativo delle cure ospedaliere e ambulatoriali nelle catene ospedaliere private. Per alleviare il problema dei sistemi sanitari, molte cliniche stanno rinviando gli appuntamenti non critici. Questo scenario sta ostacolando la crescita del trattamento della sindrome dell'intestino irritabile (IBS).

Regioni redditizie per il mercato del trattamento della sindrome dell'intestino irritabile (IBS)


Approfondimenti di mercato

Crescente prevalenza della sindrome dell'intestino irritabile e delle condizioni associate

La sindrome dell'intestino irritabile è una condizione gastrointestinale cronica prevalentemente osservata causata a causa di disturbi delle abitudini intestinali e dolori addominali. La malattia è nota anche come colon spastico, colon irritabile, colite mucosa e colite spastica. La sindrome dell’intestino irritabile mostra sintomi come dolore addominale, stitichezza, diarrea e crampi. I sistemi sanitari di tutte le regioni stanno assistendo a una crescita considerevole dell’incidenza della sindrome dell’intestino irritabile. Un dato pubblicato dalla International Foundation for Gastrointestinal Disorders afferma che tra tutti i pazienti con IBS, circa il 40% dei pazienti ha un’IBS lieve, circa il 35% ha un’IBS moderata e circa il 25% soffre di un’IBS grave. Molte persone non riconoscono i sintomi dell’IBS.

Alcuni fattori come le allergie alimentari, gli stadi di sviluppo della gastroenterite, i movimenti sporadici del colon, la composizione anormale della serotonina nel colon e la celiachia lieve sono tra i fattori di rischio che possono causare l'IBS. Si prevede che questi fattori accelereranno il tasso di prevalenza dell’IBS in tutto il mondo. Ad esempio, secondo uno studio pubblicato su NCBI nel 2018, si stima che l’IBS colpisca ogni anno circa dal 10% al 16% della popolazione statunitense. È probabile che una tale sconcertante prevalenza dell’IBS aumenterà il mercato del trattamento della sindrome dell’intestino irritabile (IBS) durante il periodo di previsione.

Approfondimenti basati sul tipo

In base al tipo, il mercato del trattamento della sindrome dell'intestino irritabile (IBS) è segmentato in IBS mista (IBS-M) , IBS con diarrea (IBS-D) e IBS con stitichezza (IBS-C). Nel 2020, il segmento IBS misto (IBS-M) deteneva la quota maggiore del mercato. Inoltre, si prevede che lo stesso segmento registrerà il CAGR più elevato durante il periodo di previsione. Si prevede che la crescente prevalenza dell’IBS tra le donne e gli uomini stimolerà la domanda di farmaci in grado di trattare i sintomi combinati di stitichezza e diarrea. La prevalenza dell’IBS è maggiore nella popolazione che invecchia. Pertanto, è probabile che la domanda di medicinali per il trattamento dell'IBS mista cresca in modo significativo durante il periodo di previsione,

mercato del trattamento della sindrome dell'intestino irritabile (IBS), per tipo: 2020 e 2028

Approfondimenti basati sul prodotto

In base al prodotto, il mercato del trattamento della sindrome dell'intestino irritabile (IBS) è segmentato in rifaximina, eluxadolina, lubiprostone , linaclotide e altri. Il segmento del linaclotide ha detenuto la quota maggiore del mercato nel 2020. Inoltre, si stima che lo stesso segmento registrerà il CAGR più elevato sul mercato durante il periodo di previsione. La crescita del mercato per il segmento è attribuita a fattori quali la crescente produzione della versione generica del linaclotide e il crescente consolidamento del mercato per lo sviluppo e la commercializzazione del linaclotide per il trattamento dell'IBS.

Approfondimenti basati sul canale di distribuzione

In base al canale di distribuzione, il mercato del trattamento della sindrome dell'intestino irritabile (IBS) è segmentato in farmacie ospedaliere, farmacie e farmacie al dettaglio e farmacie online. Nel 2020, il segmento delle farmacie ospedaliere deteneva la quota maggiore del mercato. Tuttavia, si prevede che il segmento dei drugstore e delle farmacie al dettaglio registrerà il CAGR più elevato durante il periodo di previsione.

Approfondimenti strategici

Le aziende che operano nel mercato del trattamento della sindrome dell'intestino irritabile (IBS) adottano la strategia di innovazione dei prodotti per soddisfare le richieste in evoluzione dei clienti in tutto il mondo, il che consente loro anche di mantenere il proprio marchio nel mercato globale.

Mercato del trattamento della sindrome dell'intestino irritabile (IBS) - per tipo

  • IBS con diarrea (IBS-D)
  • IBS con costipazione (IBS-C)
  • IBS mista (IBS-M)< /li>

Mercato del trattamento della sindrome dell'intestino irritabile (IBS) - per prodotto

  • Rifaximina
  • Eluxadolina
  • Linaclotide
  • Lubiprostone
  • Altro
  • < /ul>

    Mercato del trattamento della sindrome dell'intestino irritabile (IBS) - per canale di distribuzione

    • Farmacie ospedaliere
    • Drogherie e farmacie al dettaglio
    • Farmacie online

    Sindrome dell'intestino irritabile (IBS) Mercato del trattamento: per area geografica

    • Nord America
      • Stati Uniti
      • Canada
      • Messico
    • < li>Europa
      • Francia
      • Germania
      • Italia
      • Regno Unito
      • Spagna
      • Resto dell'Europa
    • Asia Pacifico (APAC)
      • Cina
      • India
      • Corea del Sud
      • Giappone
      • Australia
      • Resto dell'area APAC
    • Medio Oriente e Africa (MEA)
      • Sud Africa
      • Arabia Saudita
      • Emirati Arabi Uniti
      • Resto del MEA
    • America centrale e meridionale (SCAM )
      • Brasile
      • Argentina
      • Resto di SCAM

    Profili aziendali

    • Ironwood Pharmaceuticals, Inc.
    • AbbVie.
    • Sebela Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
    • Alfasigma SpA
    • Astellas Pharma Inc.
    • AstraZeneca
    • Synthetic Biologics, Inc.
    • Bausch + Lomb Incorporated
    • < li>Lannett Company Inc
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is irritable bowel syndrome (IBS) treatment?

Irritable bowel syndrome (IBS) is a common disorder that affects the abdominal organ, large intestine. It is also known as spastic colon, mucous colitis, irritable colon, and spastic colitis. The condition is much different than inflammatory bowel disease. However, it is a chronic condition which a person must manage for a longer period. It shows symptoms such as cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both at the same. These symptoms can be managed by changing stress, lifestyle, and diet. And the more severe symptoms are treated with medication and counseling.

What are the driving factors for the irritable bowel syndrome (IBS) treatment market across the globe?

The factors that are driving growth of the market are increasing prevalence of irritable bowel syndrome diseases and increasing research & development activities.

Who are the major players in the irritable bowel syndrome (IBS) treatment market?

The irritable bowel syndrome (IBS) treatment market majorly consists of the players such as Ironwood Pharmaceuticals, Inc., AbbVie., Sebela Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Alfasigma S.p.A., Astellas Pharma Inc., AstraZeneca, Synthetic Biologics, Inc., Bausch + Lomb Incorporated and Lannett Company Inc amongst others.

The List of Companies - Irritable Bowel Syndrome (IBS) Treatment Market

  1. Ironwood Pharmaceuticals, Inc.
  2. AbbVie.
  3. Sebela Pharmaceuticals, Inc.
  4. Takeda Pharmaceutical Company Limited
  5. Alfasigma S.p.A.
  6. Astellas Pharma Inc.
  7. AstraZeneca
  8. Synthetic Biologics, Inc.
  9. Bausch + Lomb Incorporated
  10. Lannett Company Inc

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports